West Pharma forecasts 2026 profit above estimates on strong demand for drug components [Yahoo! Finance Canada]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance Canada
Shares of the Pennsylvania-based firm were up 3.6% in ?premarket trading. Surging demand for newer diabetes and obesity treatments, including Novo Nordisk's Ozempic, Wegovy and Eli Lilly's Mounjaro, is expected to benefit medical equipment makers such as West Pharma, which supplies components for ?injection pens used ?to administer these drugs. The company now expects 2026 adjusted profit per share of $7.85 to $8.20, above analysts' estimates ?of $7.78, according to the data compiled by LSEG. First-quarter adjusted profit per share is expected at $1.65 to $1.70, compared with estimates of $1.65. Annual revenue is ?forecast to ?be between $3.22 billion and $3.28 billion, ?compared with analysts' average expectations ?of $3.25 billion. West Pharma said its revenue forecast also accounts for the sale of its SmartDose 3.5 mL on-body delivery system to AbbVie, expected to close in mid-2026. Meanwhile, fourth-quarter adjusted profit per share came in at $2.04, above estimates o
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk plans Wegovy vials amid obesity-drug competition [Yahoo! Finance]Yahoo! Finance
- Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NYSE:NVO) was upgraded by analysts at Jefferies Financial Group Inc. from an "underperform" rating to a "hold" rating.MarketBeat
- Novo CEO blasts ‘mass compounding' of GLP-1 drugs as safety battle escalates [FOX Business Network]FOX Business Network
- Novo Nordisk plans to launch Wegovy vials [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/11/26 - Form 6-K
- 2/10/26 - Form 6-K
- 2/9/26 - Form 6-K
- NVO's page on the SEC website